Avenue Therapeutics (ATXI) Competitors $1.85 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.90 +0.04 (+2.43%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends ATXI vs. NERV, PRPH, CING, SPRB, NRSN, HCWB, BGXX, FLGC, IMNN, and AIMShould you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include Minerva Neurosciences (NERV), ProPhase Labs (PRPH), Cingulate (CING), Spruce Biosciences (SPRB), NeuroSense Therapeutics (NRSN), HCW Biologics (HCWB), Bright Green (BGXX), Flora Growth (FLGC), Imunon (IMNN), and AIM ImmunoTech (AIM). These companies are all part of the "pharmaceutical products" industry. Avenue Therapeutics vs. Minerva Neurosciences ProPhase Labs Cingulate Spruce Biosciences NeuroSense Therapeutics HCW Biologics Bright Green Flora Growth Imunon AIM ImmunoTech Avenue Therapeutics (NASDAQ:ATXI) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, community ranking, valuation, risk, institutional ownership and earnings. Do analysts rate ATXI or NERV? Minerva Neurosciences has a consensus target price of $5.00, suggesting a potential upside of 129.36%. Given Minerva Neurosciences' stronger consensus rating and higher probable upside, analysts clearly believe Minerva Neurosciences is more favorable than Avenue Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Minerva Neurosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community believe in ATXI or NERV? Minerva Neurosciences received 200 more outperform votes than Avenue Therapeutics when rated by MarketBeat users. However, 60.25% of users gave Avenue Therapeutics an outperform vote while only 57.17% of users gave Minerva Neurosciences an outperform vote. CompanyUnderperformOutperformAvenue TherapeuticsOutperform Votes14760.25% Underperform Votes9739.75% Minerva NeurosciencesOutperform Votes34757.17% Underperform Votes26042.83% Which has more volatility and risk, ATXI or NERV? Avenue Therapeutics has a beta of -0.27, meaning that its stock price is 127% less volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Which has higher earnings and valuation, ATXI or NERV? Minerva Neurosciences is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvenue TherapeuticsN/AN/A-$10.38M$18.350.10Minerva NeurosciencesN/AN/A-$30M-$0.44-4.95 Do institutionals and insiders believe in ATXI or NERV? 17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 1.8% of Avenue Therapeutics shares are held by insiders. Comparatively, 8.6% of Minerva Neurosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor ATXI or NERV? In the previous week, Minerva Neurosciences had 2 more articles in the media than Avenue Therapeutics. MarketBeat recorded 2 mentions for Minerva Neurosciences and 0 mentions for Avenue Therapeutics. Avenue Therapeutics' average media sentiment score of 0.00 beat Minerva Neurosciences' score of -0.07 indicating that Avenue Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Avenue Therapeutics Neutral Minerva Neurosciences Neutral Is ATXI or NERV more profitable? Minerva Neurosciences' return on equity of 0.00% beat Avenue Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Avenue TherapeuticsN/A -471.57% -296.50% Minerva Neurosciences N/A N/A -6.74% SummaryMinerva Neurosciences beats Avenue Therapeutics on 9 of the 14 factors compared between the two stocks. Get Avenue Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATXI vs. The Competition Export to ExcelMetricAvenue TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.79M$6.58B$5.39B$9.13BDividend YieldN/A2.96%5.37%4.00%P/E Ratio0.1010.0188.8317.53Price / SalesN/A335.351,284.8380.47Price / CashN/A22.6336.6032.90Price / Book0.965.084.964.69Net Income-$10.38M$154.90M$117.89M$224.57M7 Day Performance-1.60%2.59%2.74%3.33%1 Month Performance4.52%1.52%3.63%5.33%1 Year Performance-82.39%5.49%27.26%22.97% Avenue Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATXIAvenue Therapeutics2.9599 of 5 stars$1.85flatN/A-82.4%$3.79MN/A0.104Positive NewsHigh Trading VolumeNERVMinerva Neurosciences3.3623 of 5 stars$2.24+2.8%$5.00+123.2%-71.2%$15.66MN/A-5.099Analyst ForecastNews CoveragePRPHProPhase Labs3.3904 of 5 stars$0.63-2.6%$11.00+1,639.7%-88.0%$15.10M$12.75M-0.50130CINGCingulate2.4552 of 5 stars$4.61-4.2%$12.00+160.3%+5.3%$14.81MN/A0.0020SPRBSpruce Biosciences4.0286 of 5 stars$0.35-5.1%$3.90+1,010.5%-84.7%$14.51M$7.10M-0.3720Positive NewsGap UpNRSNNeuroSense Therapeutics0.711 of 5 stars$1.02-1.9%N/A+13.5%$13.94MN/A-1.2010HCWBHCW Biologics1.6141 of 5 stars$0.37-1.0%N/A-66.4%$13.89M$3.50M-0.3740Positive NewsGap UpBGXXBright GreenN/A$0.07+3.2%N/A-68.7%$13.48MN/A-1.182FLGCFlora Growth2.1955 of 5 stars$0.93-3.5%$5.00+439.5%-43.5%$13.37M$64.15M0.00280Positive NewsIMNNImunon2.0007 of 5 stars$0.92+1.9%$20.50+2,135.1%+60.2%$13.30M$500,000.00-0.4930Short Interest ↑Positive NewsGap UpAIMAIM ImmunoTech1.8527 of 5 stars$0.21-3.7%$2.75+1,228.5%-49.1%$13.20M$190,000.00-0.4420 Related Companies and Tools Related Companies Minerva Neurosciences Alternatives ProPhase Labs Alternatives Cingulate Alternatives Spruce Biosciences Alternatives NeuroSense Therapeutics Alternatives HCW Biologics Alternatives Bright Green Alternatives Flora Growth Alternatives Imunon Alternatives AIM ImmunoTech Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ATXI) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avenue Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
